{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T16:14:38Z","timestamp":1790007278198,"version":"4.0.1"},"reference-count":60,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"11","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO Glob Oncol"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:sec>\n            <jats:title>PURPOSE<\/jats:title>\n            <jats:p>Initial reports indicate that access to contemporary therapies currently used in North America for the treatment of multiple myeloma (MM) varies internationally. No studies have quantitatively reported the extent of disparities in the access to MM therapies worldwide, with a goal to investigate access to MM therapies and barriers globally.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>METHODS<\/jats:title>\n            <jats:p>From June 18 to July 15, 2023, an electronic survey was distributed to 176 oncologists treating MM outside the United States. MM drugs were categorized by accessibility, with the cutoff for adequate access set at 60% of respondents affirming easy\/moderate access.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>RESULTS<\/jats:title>\n            <jats:p>Ninety-five (54%) respondents from 33 countries completed the survey. Fifty-one percent of the respondents were from university-based academic programs, and 17% of the responders treated only plasma cell disorders. Most respondents had adequate access to noncellular MM therapies, except for isatuximab, ixazomib, selinexor, and elotuzumab. Among the cellular therapies, 17% had access to Chimeric Antigen Receptor T-cell therapy, whereas 23% had access to approved T-cell engagers (TCEs). Financial stress on patients and health care systems has emerged as a primary barrier to global inaccessibility of treatment drugs.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSION<\/jats:title>\n            <jats:p>Global access to novel MM therapies remains challenging, and we have identified barriers and suggested strategies to bridge this gap.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1200\/go-24-00441","type":"journal-article","created":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T19:59:13Z","timestamp":1749067153000},"update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":6,"title":["Global Access to Multiple Myeloma Therapies"],"prefix":"10.1200","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-7212-0990","authenticated-orcid":true,"given":"Rawan","family":"Atallah","sequence":"first","affiliation":[{"name":"Division of Hematologic Malignancies &amp; Cellular Therapeutics, University of Kansas Medical Center, Westwood, KS"},{"name":"US Myeloma Innovations Research Collaborative (USMIRC), Westwood, KS"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-9068-5474","authenticated-orcid":true,"given":"Yara","family":"Shatnawi","sequence":"additional","affiliation":[{"name":"US Myeloma Innovations Research Collaborative (USMIRC), Westwood, KS"},{"name":"Jordan University of Science &amp; Technology, Irbid, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MD Fathima Shehnaz","family":"Ayoobkhan","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Trinity Health Oakland\/Wayne State University, Detroit, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md Saiful Islam","family":"Saif","sequence":"additional","affiliation":[{"name":"Department of Biostatistics &amp; Data Science, University of Kansas Medical Center, Kansas City, KS"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menahil","family":"Naeem","sequence":"additional","affiliation":[{"name":"International Baccalaureate, Erindale Secondary School, Mississauga, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-7639-3192","authenticated-orcid":true,"given":"Emerson","family":"Logan","sequence":"additional","affiliation":[{"name":"Division of Hematologic Malignancies &amp; Cellular Therapeutics, University of Kansas Medical Center, Westwood, KS"},{"name":"US Myeloma Innovations Research Collaborative (USMIRC), Westwood, KS"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8122-0563","authenticated-orcid":true,"given":"Muhammad Umair","family":"Mushtaq","sequence":"additional","affiliation":[{"name":"Division of Hematologic Malignancies &amp; Cellular Therapeutics, University of Kansas Medical Center, Westwood, KS"},{"name":"US Myeloma Innovations Research Collaborative (USMIRC), Westwood, KS"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shabeeha","family":"Rana","sequence":"additional","affiliation":[{"name":"American Hospital, Dubai, United Arab Emirates"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-7742-734X","authenticated-orcid":true,"given":"Aytaj","family":"Mammadzadeh","sequence":"additional","affiliation":[{"name":"US Myeloma Innovations Research Collaborative (USMIRC), Westwood, KS"},{"name":"Division of Hematology\/Oncology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahrukh K.","family":"Hashmi","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Mayo Clinic, Rochester, MN"},{"name":"Department of Medicine, Sheikh Shakhbout Medical City, Mayo Clinic, Abu Dhabi, United Arab Emirates"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benlazar","family":"Mohamed","sequence":"additional","affiliation":[{"name":"Hematology Department, University of Sidi Bel Abbe\u0300s, Sidi Bel Abbe\u0300s, Algeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nihar","family":"Desai","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Centre, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4326-7966","authenticated-orcid":true,"given":"Thiago Xavier","family":"Carneiro","sequence":"additional","affiliation":[{"name":"Hospital Ophir Loyola\/State University of Para, Bel\u00e9m, PA, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6553-4618","authenticated-orcid":true,"given":"Rakesh","family":"Popat","sequence":"additional","affiliation":[{"name":"Department of Hematology, University College London Hospitals NHS Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0539-4796","authenticated-orcid":true,"given":"Joseph P.","family":"McGuirk","sequence":"additional","affiliation":[{"name":"Division of Hematologic Malignancies &amp; Cellular Therapeutics, University of Kansas Medical Center, Westwood, KS"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4547-7534","authenticated-orcid":true,"given":"Shebli","family":"Atrash","sequence":"additional","affiliation":[{"name":"US Myeloma Innovations Research Collaborative (USMIRC), Westwood, KS"},{"name":"Department of Hematologic Oncology &amp; Blood Disorders, Atrium Health Levine Cancer Institute, Charlotte, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3168-2521","authenticated-orcid":true,"given":"Zahra","family":"Mahmoudjafari","sequence":"additional","affiliation":[{"name":"Division of Hematologic Malignancies &amp; Cellular Therapeutics, University of Kansas Medical Center, Westwood, KS"},{"name":"US Myeloma Innovations Research Collaborative (USMIRC), Westwood, KS"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7929-1450","authenticated-orcid":true,"given":"Nada","family":"Hammad","sequence":"additional","affiliation":[{"name":"UNSW, Darlinghurst, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6914-7439","authenticated-orcid":true,"given":"Faiz","family":"Anwer","sequence":"additional","affiliation":[{"name":"US Myeloma Innovations Research Collaborative (USMIRC), Westwood, KS"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4336-4982","authenticated-orcid":true,"given":"Nausheen","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Division of Hematologic Malignancies &amp; Cellular Therapeutics, University of Kansas Medical Center, Westwood, KS"},{"name":"US Myeloma Innovations Research Collaborative (USMIRC), Westwood, KS"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6603-185X","authenticated-orcid":true,"given":"Al-Ola","family":"Abdallah","sequence":"additional","affiliation":[{"name":"Division of Hematologic Malignancies &amp; Cellular Therapeutics, University of Kansas Medical Center, Westwood, KS"},{"name":"US Myeloma Innovations Research Collaborative (USMIRC), Westwood, KS"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_7_2_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2020-0141"},{"key":"e_1_3_7_3_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01296-2"},{"key":"e_1_3_7_4_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-0625"},{"key":"e_1_3_7_5_2","first-page":"135","article-title":"Velcade (bortezomib) receives 2 new FDA indications: For retreatment of patients with multiple myeloma and for first-line treatment of patients with mantle-cell lymphoma","volume":"8","author":"Raedler L","year":"2015","unstructured":"Raedler L: Velcade (bortezomib) receives 2 new FDA indications: For retreatment of patients with multiple myeloma and for first-line treatment of patients with mantle-cell lymphoma. Am Health Drug Benefits 8:135-140, 2015","journal-title":"Am Health Drug Benefits"},{"key":"e_1_3_7_6_2","doi-asserted-by":"publisher","DOI":"10.1177\/2040620720930629"},{"key":"e_1_3_7_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-016-0548-5"},{"key":"e_1_3_7_8_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-2870"},{"key":"e_1_3_7_9_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0229"},{"key":"e_1_3_7_10_2","doi-asserted-by":"publisher","DOI":"10.1177\/20406207221090089"},{"key":"e_1_3_7_11_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-0755"},{"key":"e_1_3_7_12_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.8-6-508"},{"key":"e_1_3_7_13_2","doi-asserted-by":"publisher","DOI":"10.2174\/09298673113209990198"},{"key":"e_1_3_7_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2022.04.008"},{"key":"e_1_3_7_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01793-1"},{"key":"e_1_3_7_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2018.08.005"},{"key":"e_1_3_7_17_2","unstructured":"Treatment for newly diagnosed multiple myeloma: Addressing disparities in care. https:\/\/www.onclive.com\/view\/treatment-for-newly-diagnosed-multiple-myeloma-addressing-disparities-in-care"},{"key":"e_1_3_7_18_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12082313"},{"key":"e_1_3_7_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-022-00700-7"},{"key":"e_1_3_7_20_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.2961"},{"key":"e_1_3_7_21_2","unstructured":"Health Expenditure as a Percentage of Gross Domestic Product (GDP) in Selected Countries in 2022"},{"key":"e_1_3_7_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.chbr.2022.100206"},{"key":"e_1_3_7_23_2","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_200867"},{"key":"e_1_3_7_24_2","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2021-1072"},{"key":"e_1_3_7_25_2","volume-title":"In-Myeloma-New-Drugs-Skyrocketing-Price-Tags","unstructured":"In-Myeloma-New-Drugs-Skyrocketing-Price-Tags. https:\/\/ashpublications.org\/ashclinicalnews\/news\/4501\/In-Myeloma-New-Drugs-Skyrocketing-Price-Tags"},{"key":"e_1_3_7_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30578-8"},{"key":"e_1_3_7_27_2","volume-title":"A Case Study in the Interpretation of Modern Cancer Trials","author":"The ENDEAVOR Trial","unstructured":"The ENDEAVOR Trial: A Case Study in the Interpretation of Modern Cancer Trials. https:\/\/ascopost.com\/issues\/june-10-2016\/the-endeavor-trial-a-case-study-in-the-interpretation-of-modern-cancer-trials\/"},{"key":"e_1_3_7_28_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS8055"},{"key":"e_1_3_7_29_2","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2023000434"},{"key":"e_1_3_7_30_2","unstructured":"Johnson & Johnson\u2019s blood cancer therapy gets U.S. FDA approval. https:\/\/www.reuters.com\/business\/healthcare-pharmaceuticals\/johnson-johnsons-blood-cancer-therapy-gets-us-fda-approval-2022-10-25\/"},{"key":"e_1_3_7_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2023.01.008"},{"key":"e_1_3_7_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amepre.2015.09.002"},{"key":"e_1_3_7_33_2","doi-asserted-by":"publisher","DOI":"10.2217\/fon.14.130"},{"key":"e_1_3_7_34_2","doi-asserted-by":"publisher","DOI":"10.1111\/imj.16277"},{"key":"e_1_3_7_35_2","volume-title":"Australia and New Zealand Legal and Regulatory Affairs Watchdog Update June 2023","unstructured":"Australia and New Zealand Legal and Regulatory Affairs Watchdog Update June 2023. https:\/\/www.isctglobal.org\/telegrafthub\/blogs\/lauren-reville\/2023\/06\/13\/australia-and-new-zealand-legal-and-regulatory-aff"},{"key":"e_1_3_7_36_2","unstructured":"Multiple myeloma patients await MSAC verdict on CAR T-cell therapy to manage blood cancer. https:\/\/www.abc.net.au\/news\/2024-02-01\/myeloma-cancer-patients-wait-regulator-decision-car-t-therapy\/103398250. 2024"},{"key":"e_1_3_7_37_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14112667"},{"key":"e_1_3_7_38_2","doi-asserted-by":"publisher","unstructured":"Fatoki RA Koehn K Kelkar A et al: Global myeloma trial participation and drug access in the era of novel therapies. JCO Glob Oncol 10.1200\/GO.22.00119","DOI":"10.1200\/GO.22.00119"},{"key":"e_1_3_7_39_2","unstructured":"India\u2019s first cell therapy for cancer treatment receives regulatory approval. https:\/\/www.hindustantimes.com\/cities\/mumbai-news\/indias-first-cell-therapy-for-cancer-treatment-receives-regulatory-approval-101697224829344.html"},{"key":"e_1_3_7_40_2","unstructured":"India\u2019s First Homegrown CAR T-Cell Therapy Has Roots. NCI Collaboration. https:\/\/www.cancer.gov\/news-events\/cancer-currents-blog\/2024\/nexcar19-car-t-cell-therapy-india-nci-collaboration"},{"key":"e_1_3_7_41_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.16183"},{"key":"e_1_3_7_42_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-019-0198-4"},{"key":"e_1_3_7_43_2","doi-asserted-by":"publisher","DOI":"10.1177\/2040620716652862"},{"key":"e_1_3_7_44_2","volume-title":"Addressing Challenges in Access to Oncology Medicines. Analytical Report","unstructured":"Addressing Challenges in Access to Oncology Medicines. Analytical Report. https:\/\/www.oecd.org\/health\/health-systems\/Addressing-Challenges-in-Access-to-Oncology-Medicines-Analytical-Report.pdf"},{"key":"e_1_3_7_45_2","doi-asserted-by":"publisher","DOI":"10.4337\/9781781004241.00022"},{"key":"e_1_3_7_46_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.34753"},{"key":"e_1_3_7_47_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.15_suppl.6623"},{"key":"e_1_3_7_48_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0030362"},{"key":"e_1_3_7_49_2","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_200869"},{"key":"e_1_3_7_50_2","unstructured":"Generic Drugs: Questions and Answers US Food and Drug Administration 2021. https:\/\/www.fda.gov\/drugs\/frequently-asked-questions-popular-topics\/generic-drugs-questions-answers"},{"key":"e_1_3_7_51_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2303379"},{"key":"e_1_3_7_52_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2213614"},{"key":"e_1_3_7_53_2","unstructured":"The Leukemia & Lymphoma Society: FDA's Recent Approval of 2 CAR T-Cell Therapies a \u2018Big Step Toward\u2019 Long-Term Control of Myeloma for More Patients 2024. https:\/\/www.lls.org\/news\/fdas-recent-approval-2-car-t-cell-therapies-big-step-toward-long-term-control-myeloma-more#:\u223c:text=Search-FDA's%20Recent%20Approval%20of%202%20CAR%20T%2DCell%20Therapies%20a earlier%20treatment%20of%20multiple%20myeloma"},{"key":"e_1_3_7_54_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.19462"},{"key":"e_1_3_7_55_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1397613"},{"key":"e_1_3_7_56_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2024.05.011"},{"key":"e_1_3_7_57_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01128"},{"key":"e_1_3_7_58_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00226-5"},{"key":"e_1_3_7_59_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-182628"},{"key":"e_1_3_7_60_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2018.05.005"},{"key":"e_1_3_7_61_2","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2019.7298"}],"container-title":["JCO Global Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/GO-24-00441","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T19:59:22Z","timestamp":1749067162000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/GO-24-00441"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":60,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["10.1200\/GO-24-00441"],"URL":"https:\/\/doi.org\/10.1200\/go-24-00441","relation":{},"ISSN":["2687-8941"],"issn-type":[{"value":"2687-8941","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"2024-09-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-02","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e2400441"}}